THROMBOLYTIC TREATMENT OF VENOUS THROMBI WITH COMBINED USE OF STREPTOKINASE AND HUMAN-PLASMINOGEN

被引：0
|
作者：
LUBCKE, P [1 ]
WEBER, J [1 ]
机构：
[1] ALLGEMEINE KRANKENHAUSES ALTONA, STRAHLENDIAGNOST ABT, D-2000 HAMBURG 50, FED REP GER
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 1981年 / 106卷 / 19期
关键词：
D O I：
10.1055/s-2008-1070364
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：610 / 614
页数：5
相关论文
共 50 条
  • [41] THROMBOLYTIC EFFECT OF TD-2061 (RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR) ON AGED VENOUS THROMBOSIS IN RABBIT
    MINO, T
    KOMORIYA, Y
    SUZUKI, J
    HAYASHI, H
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 121 - 121
  • [42] COMPARATIVE THROMBOLYTIC PROPERTIES OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND OF A PLASMINOGEN-ACTIVATOR INHIBITOR-1-RESISTANT GLYCOSYLATION VARIANT, IN A COMBINED ARTERIAL AND VENOUS THROMBOSIS MODEL IN THE DOG
    COLLEN, D
    STASSEN, JM
    YASUDA, T
    REFINO, C
    PAONI, N
    KEYT, B
    ROSKAMS, T
    GUERRERO, JL
    LIJNEN, HR
    GOLD, HK
    BENNETT, WF
    THROMBOSIS AND HAEMOSTASIS, 1994, 72 (01) : 98 - 104
  • [43] Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction - An analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies
    Barbash, GI
    Birnbaum, Y
    Bogaerts, K
    Hudson, M
    Lesaffre, E
    Fu, YL
    Goodman, S
    Houbracken, K
    Munsters, K
    Granger, CB
    Pieper, K
    Califf, RM
    Topol, EJ
    Van de Werf, F
    CIRCULATION, 2001, 103 (07) : 954 - 960
  • [44] Combined venous sinus angioplasty and low-dose thrombolytic therapy for treatment of hemorrhagic transverse sinus thrombosis in a pediatric patient
    Prasad, RS
    Michaels, LA
    Roychowdhury, S
    Craig, V
    Sorrell, A
    Schonfeld, S
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (03) : 196 - 199
  • [45] THROMBOLYTIC PROPERTIES OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR, SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, AND SYNERGISTIC COMBINATIONS IN VENOUS THROMBOSIS MODELS IN DOGS AND RABBITS
    SPRIGGS, DJ
    STASSEN, JM
    HASHIMOTO, Y
    COLLEN, D
    BLOOD, 1989, 73 (05) : 1207 - 1212
  • [46] Potential use of magnetotherapy and magnetostimulation in combined treatment of venous leg ulcers: a preliminary study
    Pasek, Jaroslaw
    Szajkowski, Sebastian
    Cieslar, Grzegorz
    PRZEGLAD DERMATOLOGICZNY, 2024, 111 (02): : 104 - 112
  • [47] Use of human skin equivalent in the successful treatment of chronic venous leg ulcers
    Choucair, M
    Faria, D
    Fivenson, D
    WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 1998, 10 (03): : 97 - 104
  • [48] Infusion of Recombinant Human Tissue Plasminogen Activator Through the Superior Mesenteric Artery in the Treatment of Acute Mesenteric Venous Thrombosis
    da Motta Leal Filho, Joaquim Mauricio
    Barbosa Santos, Aline Cristine
    Carnevale, Francisco Cesar
    Sousa, Wilson de Oliveira, Jr.
    Pereira Grillo, Luiz Sergio, Jr.
    Cerri, Giovanni Guido
    ANNALS OF VASCULAR SURGERY, 2011, 25 (06) : 840.e1 - 840.e4
  • [49] Safety of the Combined Use of Praziquantel and Albendazole in the Treatment of Human Hydatid Disease
    Alvela-Suarez, Lucia
    Velasco-Tirado, Virginia
    Belhassen-Garcia, Moncef
    Novo-Veleiro, Ignacio
    Pardo-Lledias, Javier
    Romero-Alegria, Angela
    Perez del Villar, Luis
    Paz Valverde-Merino, Maria
    Cordero-Sanchez, Miguel
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2014, 90 (05): : 819 - 822
  • [50] COMPARISON OF THROMBOLYTIC, FIBRINOLYTIC, AND FIBRINOGENOLYTIC PROPERTIES OF TISSUE PLASMINOGEN-ACTIVATOR, STREPTOKINASE, SINGLE-CHAIN UROKINASE, HIGH MOLECULAR-WEIGHT AND LOW-MOLECULAR WEIGHT UROKINASE IN HUMAN-PLASMA INVITRO
    SAMAMA, M
    NGUYEN, G
    DESNOYERS, P
    LOURENCO, DM
    FRETAULT, J
    HORELLOU, MH
    CONARD, J
    SZWARCER, E
    VERDY, E
    VAHANIAN, A
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1988, 2 (06) : 509 - 523
12345